Lyseplan tablets are mainly used to treat spinal muscular atrophy (SMN), a rare genetic neuromuscular disease that mainly affects infants and children, but may also occur in adults.

1、 Drug name and main ingredients

1. Common name: Risdiplam

2. Product Name: EVRYSDI ™

3. Dosage form: Oral solution (powder needs to be prepared)

4. Main ingredients: Each bottle contains 60mg of liraglutide, and the concentration after preparation is 0.75mg/mL

5. Auxiliary materials: ascorbic acid, disodium edetate, isomaltulose alcohol, mannitol, polyethylene glycol 6000, sodium benzoate, strawberry essence, sucralose, tartaric acid

2、 Indications

Spinal muscular atrophy (SMA): Used to treat SMA (including infantile and late-onset) in patients aged 2 months and above.

3、 Specifications and characteristics

1. Specification: 60mg/bottle (80mL after preparation, concentration 0.75mg/mL)

2. Appearance: The powder is light yellow to light green, and after preparation, it is a clear yellow green to yellow liquid.

4、 Usage and dosage

1. Preparation: Prepared by a pharmacist with 79mL of purified water, shaken well, and allowed to stand for 10 minutes.

2. Dose:

From 2 months to<2 years old: 0.2mg/kg/day

Age ≥ 2 and weight<20kg: 0.25mg/kg/day

Age ≥ 2 and weight ≥ 20kg: 5mg/day

3. Administration method: once a day, orally after meals or through a feeding tube. After administration, drink water to ensure complete swallowing.

4. Handling of missed doses: make-up doses can be taken within 6 hours, skipping after 6 hours; No need to take additional medication after vomiting.

5、 Dose adjustment

1. Liver dysfunction: Moderate to severe (Child Pugh B/C) is contraindicated.

2. Renal insufficiency: No adjustment required.

6、 Medication precautions

1. Monitoring requirements: Regularly check liver function, blood routine, and growth and development indicators.

2. Special Reminder:

After preparation, the solution should be refrigerated in the dark (2-8 ° C) and discarded after 64 days.

Avoid contact with skin or mucous membranes, rinse immediately if in contact.

Do not mix with formula milk or cow's milk.

7、 Medication for special populations

1. Pregnant women: Based on animal data, it may cause fetal harm, and the pros and cons need to be weighed.

2. Breastfeeding period: Suspend breastfeeding (medication may be secreted into breast milk).

3. Children: Safety has not been established for children under 2 months of age.

4. Elderly: No need to adjust dosage.

8、 Adverse reactions

1. Common (≥ 10%):

Infant type: fever, upper respiratory tract infection, pneumonia, constipation, vomiting, diarrhea, rash.

Late onset: fever, diarrhea, rash, oral ulcers.

2. Serious but rare: Retinal toxicity (animal data), QT interval prolongation.

9、 Contraindications

1. Individuals who are allergic to lisinopril or excipients.

2. Moderate to severe liver dysfunction (Child Pugh B/C).

10、 Drug interactions

1. MATE transporter substrates (such as metformin): Avoid combination therapy (which may increase toxicity).

2. CYP3A inhibitors/inducers: No significant effect.

11、 Storage method

1. Unprepared powder: Store at room temperature (15-30 ° C) and avoid light in the original packaging.

2. After preparation, the solution should be refrigerated (2-8 ° C) and discarded after 64 days.

12、 Manufacturer

Manufacturer: Genentech, Inc. (a member of Roche Group in the United States).

Note: If there is persistent fever, visual changes, or severe diarrhea during medication, seek medical attention promptly. Specific medication should be taken according to medical advice.

Evrysdiinformation